Company

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps
HKG: 2607SHA: 601607

Shanghai Pharmaceuticals Renews Sales and Distribution Agreement with Fudan‑Zhangjiang Through 2029 Under RMB 272 Million Caps

Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607; SHA: 601607) announced that it has renewed its Sales and Distribution Agreement with Shanghai Fudan‑Zhangjiang Bio‑Pharmaceutical Co., Ltd. (HKG: 1349). Under the agreement,…

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion

Gilead Q3 Product Sales Jump 13% to USD 8.3 Billion as HIV Franchise Grows 18%; Full‑Year Guidance Raised to USD 31.0–31.3 Billion

HutchMed's Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC

HutchMed’s Orpathys Plus Tagrisso Combination Wins Regulatory Review Acceptance in Europe and Japan for Post‑Tagrisso NSCLC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Sobi North America's Doptelet Approved by FDA for Pediatric ITP Treatment
Pediatric drugsProduct approvals

Sobi North America’s Doptelet Approved by FDA for Pediatric ITP Treatment

Hengrui and GSK Enter Global Licensing Pact for PDE3/4 Inhibitor HRS-9821
Auto-immuneCancer

Hengrui and GSK Enter Global Licensing Pact for PDE3/4 Inhibitor HRS-9821

Pfizer and BioNTech's LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod
BioNTechCOVID-19

Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod

Sansure Biotech's Gene Polymorphism Detection Kits Receive NMPA Class III IVD Certification
CVDProduct approvals

Sansure Biotech’s Gene Polymorphism Detection Kits Receive NMPA Class III IVD Certification

Show More